Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Alkermes |
---|---|
Information provided by: | Alkermes |
ClinicalTrials.gov Identifier: | NCT00156936 |
This is a multi-center extension of Alkermes study ALK21-006 to further assess the long-term safety of repeat monthly doses of naltrexone long acting injection.
Condition | Intervention | Phase |
---|---|---|
Alcoholism Opiate Dependence |
Drug: Naltrexone long acting injection |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | An Open-Label Multi-Center Study to Evaluate the Long-Term Safety of Naltrexone Long Acting Injection (Extension of Study ALK21-006) |
Enrollment: | 108 |
Study Start Date: | August 2004 |
Study Completion Date: | January 2007 |
Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Medisorb Naltrexone 380mg
|
Drug: Naltrexone long acting injection
IM monthly injection
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ALK21-006EXT |
Study First Received: | September 7, 2005 |
Last Updated: | January 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00156936 |
Health Authority: | United States: Food and Drug Administration |
Mental Disorders Naltrexone Alcoholism Substance-Related Disorders |
Disorders of Environmental Origin Alcohol-Related Disorders Opioid-Related Disorders Ethanol |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Narcotic Antagonists |
Peripheral Nervous System Agents Central Nervous System Agents Pharmacologic Actions |